# Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

> **NCT04038970** · PHASE2 · COMPLETED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 145 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** KN019, 5mg/kg
- **BIOLOGICAL:** KN019, 10 mg/kg
- **BIOLOGICAL:** Placebo
- **COMBINATION_PRODUCT:** Methotrexate

## Key facts

- **NCT ID:** NCT04038970
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-08
- **Primary completion:** 2022-07-28
- **Final completion:** 2022-07-28
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04038970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04038970, "Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04038970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*